Abstract Adeno-associated virus (AAV)-mediated inner ear gene therapy is a promising
treatment option for hearing loss and dizziness. Several studies have shown that AAV …

Adeno-associated viruses (AAVs) are viral vectors that offer an excellent platform for gene
therapy due to their safety profile, persistent gene expression in non-dividing cells, target …

Sensorineural hearing loss (SNHL), a highly prevalent sensory impairment, results from a
multifaceted interaction of genetic and environmental factors. As we continually gain insights …

Gene therapy for auditory diseases is gradually maturing. Recent progress in gene therapy
treatments for genetic and acquired hearing loss has demonstrated the feasibility in animal …

The mammalian inner ear consists of diverse cell types with important functions. Gene
mutations in these diverse cell types have been found to underlie different forms of genetic …

Inner ear gene therapy using adeno-associated viruses (AAVs) has been successfully
applied to several mouse models of hereditary hearing loss to improve their auditory …

Hearing loss is the most common sensory disorder. While gene therapy has emerged as a
promising treatment of inherited diseases like hearing loss, it is dependent on the …

Owing to the advances in transgenic animal technology and the advent of the next-
generation sequencing era, over 120 genes causing hereditary hearing loss have been …

Inner ear gene therapy using adeno-associated viral vectors (AAVs) in neonatal mice can
alleviate hearing loss in mouse models of deafness. However, efficient and safe transgene …

The number of patients with hearing loss is on the rise due to congenital abnormalities,
degenerative changes in old age, and acquired injuries such as virus or ototoxic drug …